Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS +0.31%82 Return-on-Tangible-Asset is 12.91% as of Dec. 2025, which is 7% above its 10-year median of 12.03. GuruFocus rates MIL:ARBS with a GF Score™ of 82/100 and a GF Value™ of €2.93 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Arterra Bioscience SpA ranks better than 92.72% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Arterra Bioscience SpA's annualizedNet Income for the quarter that ended in Dec. 2025 was €1.84 Mil. Arterra Bioscience SpA's average total tangible assets for the quarter that ended in Dec. 2025 was €14.27 Mil. Therefore, Arterra Bioscience SpA's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 12.91%.
The historical rank and industry rank for Arterra Bioscience SpA's Return-on-Tangible-Asset or its related term are showing as below:
MIL:ARBS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.65 Med: 12.03 Max: 25.72
Current: 14.36
During the past 9 years, Arterra Bioscience SpA's highest Return-on-Tangible-Asset was 25.72%. The lowest was 8.65%. And the median was 12.03%.
MIL:ARBS's Return-on-Tangible-Asset is ranked better than 92.72% of 1415
companies
in the Biotechnology industry
Industry Median: -36.15
vs MIL:ARBS: 14.36
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Arterra Bioscience SpA Return-on-Tangible-Asset Related Terms
Arterra Bioscience SpA Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 12.91% mean?
Arterra Bioscience SpA (MIL:ARBS) has a Return-on-Tangible-Asset of 12.91% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Arterra Bioscience SpA and its competitors. This is near median its historical median of 12.03. Over the past decade, Arterra Bioscience SpA's Return-on-Tangible-Asset has ranged from 8.65 to 25.72. According to the industry distribution chart, Arterra Bioscience SpA ranks #103 out of 1415 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Arterra Bioscience SpA's Return-on-Tangible-Asset too high?
Arterra Bioscience SpA's current Return-on-Tangible-Asset of 12.91% is near median its 10-year median of 12.03. Over the past 10 years, this metric has ranged from a low of 8.65 to a high of 25.72. Based on the distribution chart, Arterra Bioscience SpA ranks #103 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arterra Bioscience SpA has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #103 out of 1415 companies for Return-on-Tangible-Asset. This places Arterra Bioscience SpA in the top 7% of its industry — outperforming the majority of peers. Historically, Arterra Bioscience SpA's own Return-on-Tangible-Asset has ranged from 8.65 to 25.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current Return-on-Tangible-Asset is 12.91%, which is near median its own 10-year median of 12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.93, compared to a current price of €3.19 — trading 8.9% above its estimated fair value. The current Return-on-Tangible-Asset is 12.91%, which is near median its 10-year median of 12.03. Arterra Bioscience SpA's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Return-on-Tangible-Asset is 12.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.19 is trading 8.9% above its estimated GF Value™ of €2.93.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Return-on-Tangible-Asset: 12.91% (near median its 10-year median of 12.03)
GF Value™: €2.93 vs. price of €3.19 (8.9% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
82GF Score
Get the complete analysis for MIL:ARBS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
